Cancer News and Research

Latest Cancer News and Research

Program reduces cervical cancer deaths among HIV-infected women in Zambia

A new study undertaken in Zambia shows that, using setting-appropriate human resources and technology, morbidity and mortality from cervical cancer among HIV-infected women can be reduced. The study’s lead author is Dr Groesbeck Parham, Professor of Gynecologic Oncology and Infectious Diseases, University of Alabama at Birmingham, and Director of the Centre for Infectious Disease Research in Zambia’s Cervical Cancer Prevention Program. The research was published in the December issue of HIV Therapy.

14 Dec 2010

Health report card for NSW

The latest report on NSW health shows that it is better than most in heart disease and cancer statistics. However 60% of the state are overweight or obese says the report and 70% of the NSW adults say they have been diagnosed with long-term illnesses.

14 Dec 2010

Glycotope receives innovation award 2010 for GlycoExpress technology platform

Glycotope GmbH, a leading glycobiology company, has won the innovation award 2010 jointly presented by the German states of Berlin and Brandenburg in recognition of the company's GlycoExpress™ technology platform. GlycoExpress™ combines a very efficient improvement of the activities and side effects of a broad range of protein biopharmaceuticals with the suitability for a much broader patient population and a very high productivity.

14 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

Provectus commences PH-10 Phase 2c trial for psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.

14 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Unigene Laboratories, Inc. today announced that the Company entered into an amended and restated exclusive worldwide license agreement with GlaxoSmithKline (GSK) to develop and commercialize an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women and plans to initiate a Phase 2 study in the first quarter of 2011.

14 Dec 2010

Grey's Anatomy features patient with von Hippel-Lindau disease

The second episode in a three-part series on Grey's Anatomy features a patient with von Hippel-Lindau disease (VHL). The next new episode in the show is expected to air on January 6. The first episode, "Adrift and at Peace," aired Dec. 2.

14 Dec 2010

Scientists discover new way in which HPV triggers cancer

University of Manchester scientists have discovered for the first time an important new way in which the human papilloma virus (HPV) triggers cancer in what could lead to new treatments for cervical and mouth cancer.

14 Dec 2010

ICESP selects Ekahau RTLS for staff tracking solution

Ekahau Inc., the worldwide leader in high performance Wi-Fi-based Real Time Location Systems, today announced that Ekahau RTLS is being utilized as the underlying real-time tracking and bi-directional communications technology for a staff tracking solution at Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira - ICESP, part of the "Sistema FMUSP-HC" system, which is the largest public cancer treatment center in Latin America.

14 Dec 2010

Scientists perform metagenomic analysis of bacterial immune system for personalized oral health care

The human body is home to a complex ecosystem of microbes increasingly recognized as having a critical role in both health and disease.

14 Dec 2010

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

Prince of Wales Hospital in Hong Kong, China, has become the first treatment center in Asia to commence treating cancer patients using the UNIQUE™ medical linear accelerator from Varian Medical Systems (NYSE: VAR).

14 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

We live longer, but not healthier

Increased life expectancy in the United States has not been accompanied by more years of perfect health, reveals new research published in the December issue of the Journal of Gerontology.

14 Dec 2010

Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence

Orexo AB announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence.

14 Dec 2010

Diamyd Medical issues new shares to cover social security contributions for employee stock option plans

In connection with the exercise of employee stock options in the plans 2007/2010 and 2008/2011, Diamyd Medical is issuing 155,352 new shares of series B to cover social security contributions for the plans. The shares are issued with support of underlying warrants that covers the company's obligations within the scope of the programs.

14 Dec 2010

Roche launches new xCELLigence System RTCA HT Instrument

The new xCELLigence System RTCA HT Instrument from Roche Diagnostics rounds out the company's portfolio in real-time cell analysis with a high-throughput product. The new instrument merges the power and flexibility of xCELLigence System technology with high-throughput analyses and workflows for automated screening applications.

From Roche Sequencing and Life Science 14 Dec 2010

The Affordable Care Act can benefit 18.3 million men and women ages 50 to 64

18.3 million men and women ages 50 to 64 stand to benefit from provisions in the Affordable Care Act, assure that all health insurance provides a standard comprehensive benefit, prevent insurers from denying coverage or charging higher premiums to people with pre-existing conditions, and eliminate lifetime and annual limits in health insurance policies, according to a new Commonwealth Fund report released today.

14 Dec 2010

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.

14 Dec 2010

Cancer News and Research

Latest Cancer News and Research

Program reduces cervical cancer deaths among HIV-infected women in Zambia

Health report card for NSW

Glycotope receives innovation award 2010 for GlycoExpress technology platform

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Provectus commences PH-10 Phase 2c trial for psoriasis

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Unigene enters agreement with GSK to advance oral PTH Phase 2 program for osteoporosis

Grey's Anatomy features patient with von Hippel-Lindau disease

Scientists discover new way in which HPV triggers cancer

ICESP selects Ekahau RTLS for staff tracking solution

Scientists perform metagenomic analysis of bacterial immune system for personalized oral health care

Chinese hospital uses UNIQUE radiotherapy system to treat cancer patients

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

We live longer, but not healthier

Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence

Diamyd Medical issues new shares to cover social security contributions for employee stock option plans

Roche launches new xCELLigence System RTCA HT Instrument

The Affordable Care Act can benefit 18.3 million men and women ages 50 to 64

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in